This study focuses on patients with metastatic colorectal cancer, specifically the MSS/pMMR subtype. The research aims to test a new approach using patient-derived tumouroids (laboratory-grown tumor cells) to help doctors choose between two different chemotherapy combinations for treatment. The study compares two treatment options: an oxaliplatin-based therapy and an irinotecan-based therapy, both given through intravenous infusion.
The treatments being studied include two different combinations of chemotherapy drugs. The first combination contains Oxaliplatin Fresenius Kabi as a solution for infusion, which can be given up to 200 mg per square meter of body surface area per day. The second combination contains Irinotecan Fresenius Kabi as a solution for infusion, which can be given up to 400 mg per square meter of body surface area per day. Both treatments may be given for up to 12 months.
During the study, small samples of tumor tissue will be collected and grown in a laboratory to create tumouroids. These laboratory-grown samples will be tested to see how they respond to different chemotherapy combinations. This information will help determine which treatment might work better for each patient. The study will track how well patients respond to treatment, how long the treatment keeps the cancer under control, and any side effects that may occur.
Norway 
